Foreign firms may be re-calibrating their India market strategy but wider concerns of their waning interest in the ultra-competitive and largely out-of-pocket market may be unfounded, at least for now.
Foreign Firms Not Fatigued In India, Game For 'New Things'
Senior management executives of Roche, Bayer, AstraZeneca, Pfizer and Novo Nordisk in India signal momentum in product launch and clinical trial activity, belying apprehension of wider cutbacks by foreign firms in the country, though one executive stressed that “tried and tested models” may not work in the largely self-pay market.
